Ixekizumab for acrodermatitis continua

Pilz, Anna Caroline; Roenneberg, Sophie; Biedermann, Tilo; Eyerich, Kilian

doi:10.1111/ddg.13568

Cited by 4 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 These therapies include topical agents (corticosteroids, tar, calcipotriol, dithranol, fluorouracil, and calcineurin inhibitors); phototherapy (psoralen ultraviolet A (PUVA)/ultraviolet B (UVB)); and systemic medications (oral corticosteroids, methotrexate, cyclosporine, retinoids, tetracyclines, colchicine, dapsone, and various biologics). 1,3 Our patient failed conventional plaque psoriasis monotherapy, but the initiation of adalimumab, in addition to alitretinoin and clobetasol propionate, provided disease control without side effects other than xerophthalmia.…”

Section: Discussionmentioning

confidence: 83%

Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report

Crowley

Maliyar

Rodriguez-Bolanos

et al. 2019

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Acrodermatitis continua of Hallopeau is a chronic, inflammatory, and relapsing condition that presents as pustules of the fingers and toes, often with nail involvement. This condition is infrequently reported, difficult to treat, and often misdiagnosed. Various anti-psoriatic therapies have been used, but literature is limited to case studies with equivocal results. Biological therapy is revolutionizing the management of many dermatologic conditions and is believed to be a promising option for acrodermatitis continua of Hallopeau patients who have failed conventional therapy. We report the 4-year treatment course of a 70-year-old woman with acrodermatitis continua of Hallopeau that was initially unsuccessful with conventional treatments but successfully treated with the tumor necrosis factor alpha inhibitor adalimumab, in combination with alitretinoin and clobetasol propionate. This case adds to the current understanding of acrodermatitis continua of Hallopeau and the potential of biological therapy, in our case, adalimumab, for acrodermatitis continua of Hallopeau management. Literature should continue growing to ascertain the safety and efficacy of biologic therapy for patients with acrodermatitis continua of Hallopeau.

show abstract

Section: Discussionmentioning

confidence: 83%

Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report

Crowley

Maliyar

Rodriguez-Bolanos

et al. 2019

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…When systemic agents are not effective or not suitable options, biologic therapy has shown promise in the management of this challenging condition. 72 42/Female Secukinumab Success; 1-time treatment One 300 mg injection Pilz et al 63 60/Female Ixekizumab Success; 12 weeks of treatment 160 mg at week 0, followed by 80 mg every 2 weeks from weeks 2 to 12…”

Section: Resultsmentioning

confidence: 99%

“…Interestingly, there has also been 1 case report of a psoriasiform eruption involving the fingertips and nails emerging subsequent to initiation of secukinumab for the treatment of plaque psoriasis highlighting the complex interplay of cytokines in this group of conditions. 24,[62][63][64]…”

Section: Il-17 Inhibitorsmentioning

confidence: 99%

The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review

et al. 2019

View full text Add to dashboard Cite

Acrodermatitis continua of Hallopeau is a rare subtype of pustular psoriasis that presents as a sterile, pustular eruption commonly in the finger tips and toes. This disease inflicts both the skin and nail bed, and causes severe disfigurement of the distal phalanges. Because it is a variant of pustular psoriasis, acrodermatitis continua of Hallopeau is commonly managed with antipsoriatic medications. Common approaches to treatment include topical therapy (corticosteroids, vitamin D analogs, and calcineurin inhibitors), systemic therapy, and in more severe cases, biologic therapy. This review will discuss how acrodermatitis continua of Hallopeau is diagnosed and how it is managed, with a particular emphasis on the use of biologics.

show abstract

“… 12 A review of the literature has identified case reports of ACH successfully treated with different IL-17 inhibitors such as brodalumab, secukinumab, and ixekizumab. 14 – 20 However, the role of IL-17 inhibition in the development of pustular psoriasis is not fully understood, and a case of “paradoxical” pustular psoriasis has been reported in a patient receiving secukinumab treatment for plaque psoriasis. 21 …”

Section: Discussionmentioning

confidence: 99%

“…12 A review of the literature has identified case reports of ACH successfully treated with different IL-17 inhibitors such as brodalumab, secukinumab, and ixekizumab. [14][15][16][17][18][19][20] However, the role of IL-17 inhibition in the development of pustular psoriasis is not fully understood, and a case of "paradoxical" pustular psoriasis has been reported in a patient receiving secukinumab treatment for plaque psoriasis. 21 Bimekizumab, a monoclonal IgG1 antibody that acts as a selective inhibitor of both IL-17A and IL-17F, has been found be a safe and effective treatment for patients with moderate-to-severe plaque psoriasis, and is capable of achieving high rates of skin clearance when dosed every 4 or 8 weeks.…”

Section: Discussionmentioning

confidence: 99%

Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report

Cirone

Lovegrove

2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Acrodermatitis continua of Hallopeau is a rare variant of localized pustular psoriasis characterized by the recurrent eruption of sterile pustules involving the distal portions of the fingers and toes that can lead to the destruction of the nail apparatus. Acrodermatitis continua of Hallopeau is a chronic, relapsing condition that is resistant to most topical and systemic psoriasis therapies, making it notoriously difficult to manage. Interleukin-36 and interleukin-17 are thought to play a pivotal role in the pathophysiology of pustular psoriasis, and evidence suggests that interleukin-17 inhibition can be an effective therapy for pustular psoriasis variants, including acrodermatitis continua of Hallopeau. Bimekizumab, a monoclonal antibody that inhibits the interleukin-17 pathway, may be a safe and effective treatment option for patients with acrodermatitis continua of Hallopeau. We present the first documented case of a patient with acrodermatitis continua of Hallopeau of the bilateral thumbnails who experienced an excellent response to bimekizumab treatment.

show abstract

Ixekizumab for acrodermatitis continua

Cited by 4 publications

References 10 publications

Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report

Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report

The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review

Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report

Contact Info

Product

Resources

About